Clinical Study
Systemic Factors Associated with Treatment Response in Diabetic Macular Edema
Table 1
Patient demographics, clinical, and ocular characteristics (n = 35).
| | Parameter | | | Number (percentage) |
| | Demographics | Gender | Male | 17 (48.6) | | Female | 18 (51.4) | | Age | Mean/SD | 62.1 yrs/SD-7.4 | | Range | 50–80 yrs |
| | Treatment for diabetes mellitus | Oral hypoglycemic agents | 20 (57.14) | | Only insulin | 4 (11.4) | | Insulin + oral hypoglycemic agents | 11 (31.4) |
| | Comorbidities | Hypertension | 34 (97.1) | | Ischemic heart disease | 11 (31.4) | | Nephropathy | 17 (48.6) | | On renal dialysis | 3 (8.6) |
| | Ocular features | Snellen best corrected visual acuity | 6/12 or better | 21 (60) | | >6/60 to <6/12 | 11 (34) | | ≤6/60 | 3 (8.6) | | Lens status | Minimal cataract | 19 (54.3) | | Significant cataract | 8 (22.9) | | Pseudophakia | 8 (22.9) | | Proliferative diabetic retinopathy | 2 (5.7) | |
| | Prior treatment for diabetic retinopathy/maculopathy | Previous laser | PRP | 18 (51.4) | | Macular | 6 (17.1) | | Both | 2 (5.7) | | Prior intravitreal anti-VEGF therapy | 23 (65.7) |
|
|
SD, standard deviation; PRP, pan retinal photocoagulation; anti-VEGF, antivascular endothelial growth factor.
|
